The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase

Overview

Journal Cell Chem Biol

Publisher Cell Press

Specialty Biochemistry

Date 2018 Sep 4

PMID 30174310

Citations 16

Authors

Yuki Takamatsu

Debananda Das

Satoru Kohgo

Hironori Hayashi

Nicole S Delino

Stefan G Sarafianos

Hiroaki Mitsuya

Kenji Maeda

Affiliations

Soon will be listed here.

Abstract

4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA/MK-8591), a nucleoside reverse transcriptase inhibitor (NRTI) under clinical trials, is a potent and promising long-acting anti-HIV type 1 (HIV-1) agent. EFdA and its derivatives possess a modified 4'-moiety and potently inhibit the replication of a wide spectrum of HIV-1 strains resistant to existing NRTIs. Here, we report that EFdA and NRTIs with a 4'-ethynyl- or 4'-cyano-moiety exerted activity against HIV-1 with an M184V mutation and multiple NRTI-resistant HIV-1s, whereas NRTIs with other moieties (e.g., 4'-methyl) did not show this activity. Structural analysis indicated that EFdA and 4'-ethynyl-NRTIs (but not other 4'-modified NRTIs), formed strong van der Waals interactions with critical amino acid residues of reverse transcriptase. Such interactions were maintained even in the presence of a broad resistance-endowing M184V substitution, thus potently inhibiting drug-resistant HIV-1 strains. These findings also explain the mechanism for the potency of EFdA and provide insights for further design of anti-HIV-1 therapeutics.

Citing Articles

Modeling of HIV-1 prophylactic efficacy and toxicity with islatravir shows non-superiority for oral dosing, but promise as a subcutaneous implant.

Kim H, Zhang L, Hendrix C, Haberer J, von Kleist M CPT Pharmacometrics Syst Pharmacol. 2024; 13(10):1693-1706.

PMID: 39164932 PMC: 11494919. DOI: 10.1002/psp4.13212.

No antagonism or cross-resistance and a high barrier to the emergence of resistance for the combination of islatravir and lenacapavir.

Diamond T, Goh S, Ngo W, Rodriguez S, Xu M, Klein D Antimicrob Agents Chemother. 2024; 68(7):e0033424.

PMID: 38864613 PMC: 11232396. DOI: 10.1128/aac.00334-24.

HIV-1 Resistance to Islatravir/Tenofovir Combination Therapy in Wild-Type or NRTI-Resistant Strains of Diverse HIV-1 Subtypes.

Cilento M, Wen X, Reeve A, Ukah O, A Snyder A, Carrillo C Viruses. 2023; 15(10).

PMID: 37896768 PMC: 10612037. DOI: 10.3390/v15101990.

A novel anti-HBV agent, E-CFCP, restores Hepatitis B virus (HBV)-induced senescence-associated cellular marker perturbation in human hepatocytes.

Takamatsu Y, Hayashi S, Kumamoto H, Imoto S, Tanaka Y, Mitsuya H Virus Res. 2023; 329:199094.

PMID: 36933835 PMC: 10194405. DOI: 10.1016/j.virusres.2023.199094.

Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs).

Diamond T, Ngo W, Xu M, Goh S, Rodriguez S, Lai M Antimicrob Agents Chemother. 2022; 66(6):e0013322.

PMID: 35546110 PMC: 9211433. DOI: 10.1128/aac.00133-22.

References

Smith R, Raugi D, Wu V, Leong S, Parker K, Oakes M . The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1. Antimicrob Agents Chemother. 2015; 59(12):7437-46. PMC: 4649195. DOI: 10.1128/AAC.01326-15. View

Takamatsu Y, Tanaka Y, Kohgo S, Murakami S, Singh K, Das D . 4'-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus. Hepatology. 2015; 62(4):1024-36. PMC: 4589464. DOI: 10.1002/hep.27962. View

Das K, Xiong X, Yang H, Westland C, Gibbs C, Sarafianos S . Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol. 2001; 75(10):4771-9. PMC: 114232. DOI: 10.1128/JVI.75.10.4771-4779.2001. View

Kohgo S, Horie H, Ohrui H . Synthesis of 4'-C-ethynyl-beta-D-arabino- and 4'-C-ethynyl-2'-deoxy-beta- D-ribo-pentofuranosyl pyrimidines, and their biological evaluation. Biosci Biotechnol Biochem. 1999; 63(6):1146-9. DOI: 10.1271/bbb.63.1146. View

Michailidis E, Marchand B, Kodama E, Singh K, Matsuoka M, Kirby K . Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor. J Biol Chem. 2009; 284(51):35681-91. PMC: 2790999. DOI: 10.1074/jbc.M109.036616. View

Huang H, Chopra R, Verdine G, Harrison S . Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science. 1998; 282(5394):1669-75. DOI: 10.1126/science.282.5394.1669. View

Allen M, Deslauriers M, Andrews C, Tipples G, Walters K, Tyrrell D . Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology. 1998; 27(6):1670-7. DOI: 10.1002/hep.510270628. View

Brenner B, Coutsinos D . The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications. HIV Ther. 2010; 3(6):583-594. PMC: 2826981. DOI: 10.2217/hiv.09.40. View

Adachi A, Gendelman H, Koenig S, Folks T, Willey R, Rabson A . Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol. 1986; 59(2):284-91. PMC: 253077. DOI: 10.1128/JVI.59.2.284-291.1986. View

10.

Michailidis E, Ryan E, Hachiya A, Kirby K, Marchand B, Leslie M . Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA. Retrovirology. 2013; 10:65. PMC: 3695782. DOI: 10.1186/1742-4690-10-65. View

11.

Menendez-Arias L . Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antiviral Res. 2013; 98(1):93-120. DOI: 10.1016/j.antiviral.2013.01.007. View

12.

Ohrui H, Kohgo S, Kitano K, Sakata S, Kodama E, Yoshimura K . Syntheses of 4'-C-ethynyl-beta-D-arabino- and 4'-C-ethynyl-2'-deoxy-beta-D-ribo-pentofuranosylpyrimidines and -purines and evaluation of their anti-HIV activity. J Med Chem. 2000; 43(23):4516-25. DOI: 10.1021/jm000209n. View

13.

Wu V, Smith R, Masoum S, Raugi D, Ba S, Seydi M . MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture. Antimicrob Agents Chemother. 2017; 61(8). PMC: 5527656. DOI: 10.1128/AAC.00744-17. View

14.

Miller M . K65R, TAMs and tenofovir. AIDS Rev. 2004; 6(1):22-33. View

15.

Van Eygen V, Thys K, Van Hove C, Rimsky L, De Meyer S, Aerssens J . Deep sequencing analysis of HIV-1 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE. J Med Virol. 2015; 88(5):798-806. DOI: 10.1002/jmv.24395. View

16.

Kohgo S, Yamada K, Kitano K, Iwai Y, Sakata S, Ashida N . Design, efficient synthesis, and anti-HIV activity of 4'-C-cyano- and 4'-C-ethynyl-2'-deoxy purine nucleosides. Nucleosides Nucleotides Nucleic Acids. 2004; 23(4):671-90. DOI: 10.1081/NCN-120037508. View

17.

Larder B, Kemp S, Purifoy D . Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Proc Natl Acad Sci U S A. 1989; 86(13):4803-7. PMC: 297503. DOI: 10.1073/pnas.86.13.4803. View

18.

Powderly W . Osteoporosis and bone health in HIV. Curr HIV/AIDS Rep. 2012; 9(3):218-22. DOI: 10.1007/s11904-012-0119-7. View

19.

Maag H, Rydzewski R, McRoberts M, Verheyden J, Prisbe E . Synthesis and anti-HIV activity of 4'-azido- and 4'-methoxynucleosides. J Med Chem. 1992; 35(8):1440-51. DOI: 10.1021/jm00086a013. View

20.

Leeansyah E, Cameron P, Solomon A, Tennakoon S, Velayudham P, Gouillou M . Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis. 2013; 207(7):1157-65. DOI: 10.1093/infdis/jit006. View